Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Int J Cancer. 2015 May 19;137(9):2243–2252. doi: 10.1002/ijc.29588

Table 2.

Summary for m708.5 in combination with drugs against neuroblastoma.

Drugs LAN-1
SK-N-MM
m708.5 Drug CIa ± SD Effectb m708.5 Drug CIa ± SD Effectb
SN38 0.3μg/ml 0.4–100nmol/L 0.37 ± 0.05 synergism 0.6μg/ml 0.4–100nmol/L 0.48 ± 0.05 synergism
doxorubicin 0.3μg/ml 0.08–2μmol/L 0.52 ± 0.03 synergism 0.6μg/ml 0.08–2μmol/L 0.61 ± 0.12 synergism
vincristine 0.3μg/ml 0.2–60nmol/L 0.6 ± 0.19 synergism 0.6μg/ml 0.2–60 0.59 ± 0.02 synergism
cisplatin 0.3μg/ml 0.4–100μmol/L 0.80 ± 0.00 moderate synergism 0.6v 0.4–100μmol/L 1.28 ± 0.07 moderate antagonism
temsirolimus 0.3μg/ml 0.2–5μmol/L 0.49 ± 0.28 synergism 0.6μg/ml 0.2–5μmol/L 0.18 ± 0.04 strong synergism
a

CI, combination index

b

definition of CI values, <0.1(very strong synergism); 0.1–0.3 (strong synergism); 0.3–0.7 (synergism); 0.7–0.85 (modest synergism); 0.85–0.9 (slight synergism); 0.9–1.1 (nearly additive); 1.1–1.2 (slight antagonism); 1.2–1.45 (modest antagonism); 1.45–3.3 (antagonism);3.3–10 (strong antagonism); >10 (very strong antagonism).